A post mortem study of an AD patient who had undergone ante mortem [18F]THK-5351 (Figure 3g) PET demonstrated [3H]THK-5351 binding to MAO-B, which was compatible with previous PET findings [128], thus arguably disqualifying [18F]THK-5351 (Figure 3g) as a selective tau biomarker in AD diagnosis. This evidence concerns the gene MAPT and Alzheimer disease.